These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 30746140)

  • 21. Ischemic Stroke During Daprodustat Therapy for Renal Anemia: A Report of Three Cases.
    Uchio N; Komaki S; Hao A; Matsumoto H
    Cureus; 2024 Apr; 16(4):e57990. PubMed ID: 38738133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia.
    Mahar KM; Yang S; Mesic E; Post TM; Goulooze SC
    Clin Pharmacokinet; 2024 Sep; 63(9):1327-1341. PubMed ID: 39259485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
    Akizawa T; Otsuka T; Reusch M; Ueno M
    Ther Apher Dial; 2020 Apr; 24(2):115-125. PubMed ID: 31222951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Different Doses of Daprodustat for Anemic Non-dialysis Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.
    Fadlalmola H; Al-Sayaghi K; Al-Hebshi A; Aljohani M; Albalawi M; Kashari O; Alem A; Alrasheedy M; Balelah S; Almuteri F; Alyamani A; Alwasaidi T
    J Clin Med; 2022 May; 11(10):. PubMed ID: 35628849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
    Provenzano R; Bhaduri S; Singh AK;
    Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daprodustat for anaemia in patients with heart failure and chronic kidney disease: A randomized controlled study.
    Iso T; Matsue Y; Mizukami A; Tokano T; Isoda K; Suwa S; Miyauchi K; Yanagisawa N; Okumura Y; Minamino T
    ESC Heart Fail; 2022 Dec; 9(6):4291-4297. PubMed ID: 35983622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Single-Dose, Open-Label, Randomized, Two-Way Crossover Study in Healthy Japanese Participants to Evaluate the Bioequivalence and the Food Effect on the Pharmacokinetics of Daprodustat.
    Yamada M; Osamura M; Ogura H; Onoue T; Wakamatsu A; Numachi Y; Caltabiano S; Mahar KM
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):978-984. PubMed ID: 32250021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
    Provenzano R; Besarab A; Wright S; Dua S; Zeig S; Nguyen P; Poole L; Saikali KG; Saha G; Hemmerich S; Szczech L; Yu KH; Neff TB
    Am J Kidney Dis; 2016 Jun; 67(6):912-24. PubMed ID: 26846333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
    J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Roxadustat for CKD-related Anemia in Non-dialysis Patients.
    Coyne DW; Roger SD; Shin SK; Kim SG; Cadena AA; Moustafa MA; Chan TM; Besarab A; Chou W; Bradley C; Eyassu M; Leong R; Lee TT; Saikali KG; Szczech L; Yu KP
    Kidney Int Rep; 2021 Mar; 6(3):624-635. PubMed ID: 33732977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
    Akizawa T; Ueno M; Shiga T; Reusch M
    Ther Apher Dial; 2020 Dec; 24(6):628-641. PubMed ID: 31891449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial.
    Akizawa T; Nangaku M; Yamaguchi T; Arai M; Koretomo R; Matsui A; Hirakata H
    Am J Nephrol; 2019; 49(2):165-174. PubMed ID: 30699415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease.
    Hertel JE; Locay HR; Scarlata DS; Prathikanti R; Audhya PK
    Mayo Clin Proc; 2006 Sep; 81(9):1188-94. PubMed ID: 16970215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL.
    Ayus JC; Go AS; Valderrabano F; Verde E; de Vinuesa SG; Achinger SG; Lorenzo V; Arieff AI; Luño J;
    Kidney Int; 2005 Aug; 68(2):788-95. PubMed ID: 16014057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents.
    Silver MR; Geronemus R; Krause M; Chen CY; Kewalramani R; Stehman-Breen C
    Curr Med Res Opin; 2009 Jan; 25(1):123-31. PubMed ID: 19210145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients.
    Nangaku M; Farag YMK; deGoma E; Luo W; Vargo D; Khawaja Z
    Nephrol Dial Transplant; 2020 Jul; ():. PubMed ID: 32719868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation.
    Baron F; Sautois B; Baudoux E; Matus G; Fillet G; Beguin Y
    Exp Hematol; 2002 Jun; 30(6):546-54. PubMed ID: 12063021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease.
    Ishii T; Tanaka T; Nangaku M
    Ther Clin Risk Manag; 2021; 17():155-163. PubMed ID: 33628028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics.
    Chertow GM; Pergola PE; Agarwal R; Block GA; Farag YMK; Jardine AG; Koury MJ; Luo W; Khawaja Z; Lewis EF; Matsushita K; McCullough PA; Parfrey PS; Wittes J; Walters KA; Tseng C; Lin T; Sarnak MJ; Vargo DL; Winkelmayer WC; Eckardt KU
    Am Heart J; 2021 May; 235():1-11. PubMed ID: 33129989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.